Alfresa HoldingsALFRY 75 PE Ratio without NRI is 14.63 as of Jul. 01, 2026, which is 7% below its 10-year median of 15.73. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.31 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 87 Medical Distribution companies, Alfresa Holdings ranks better than 50.57% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-01), Alfresa Holdings's share price is $13.80.
Alfresa Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.94. Therefore, Alfresa Holdings's PE Ratio without NRI for today is 14.63.
During the past 13 years, Alfresa Holdings's highest PE Ratio without NRI was 22.42. The lowest was 10.55. And the median was 15.73.
Alfresa Holdings Corp stock PE Ratio (=9.48) is close to 10-year low of 9.48.
During the past years, Alfresa Holdings's highestPE Ratio (TTM) was 19.17. The lowest was 9.48. And the median was 14.07.
Alfresa Holdings's
EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.34.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.49.
Alfresa Holdings's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.34.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.49.
Alfresa Holdings (OTCPK:ALFRY) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Alfresa Holdings PE Ratio without NRI Related Terms
Alfresa Holdings PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALFRY vs MCK, CAH, COR: PE Ratio without NRI Comparison
For the Medical Distribution subindustry, Alfresa Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Alfresa Holdings's PE Ratio without NRI for today is calculated as
Alfresa Holdings's Share Price of today is $13.80.
Alfresa Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Alfresa Holdings (ALFRY) has a PE Ratio without NRI of 14.63 as of Jul. 01, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Alfresa Holdings and its competitors. This is near median its historical median of 15.73. Over the past decade, Alfresa Holdings' PE Ratio without NRI has ranged from 10.55 to 22.42. According to the industry distribution chart, Alfresa Holdings ranks #43 out of 87 companies in the Medical Distribution industry, placing it in the top 49.4%.
Is Alfresa Holdings' PE Ratio without NRI too high?
Alfresa Holdings' current PE Ratio without NRI of 14.63 is near median its 10-year median of 15.73. Over the past 10 years, this metric has ranged from a low of 10.55 to a high of 22.42. The Medical Distribution industry median PE Ratio without NRI is 15.24. Alfresa Holdings' value of 14.63 is 4% below this industry median. Based on the distribution chart, Alfresa Holdings ranks #43 out of 87 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' PE Ratio without NRI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #43 out of 87 companies for PE Ratio without NRI. This puts Alfresa Holdings in the upper half of its industry. The industry median PE Ratio without NRI is 15.24. Alfresa Holdings' value of 14.63 is 4% below this benchmark. Historically, Alfresa Holdings' own PE Ratio without NRI has ranged from 10.55 to 22.42 over the past decade. While the company's 10-year median is 15.73 vs. the industry median of 15.24, Alfresa Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Distribution company?
The median PE Ratio without NRI among Medical Distribution companies is 15.24, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current PE Ratio without NRI of 14.63 is 4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median PE Ratio without NRI is 15.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current PE Ratio without NRI is 14.63, which is near median its own 10-year median of 15.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.31, compared to a current price of $13.80 — trading 15.4% below its estimated fair value. The current PE Ratio without NRI is 14.63, which is near median its 10-year median of 15.73 and 4% below the Medical Distribution industry median of 15.24. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current PE Ratio without NRI is 14.63 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.80 is trading 15.4% below its estimated GF Value™ of $16.31.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
PE Ratio without NRI: 14.63 (near median its 10-year median of 15.73)
GF Value™: $16.31 vs. price of $13.80 (15.4% below fair value)
Industry Position: 4% below the Medical Distribution median (#43 of 87)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
